AKT2

Across TCGA pan-cancer cohorts, AKT2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of AKT2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where AKT2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AKT2 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and PDAC are the cancer types where AKT2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AKT2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	−0.313	<.001	8	view →
COAD	All	All	−0.147	<.001	8	view →
PDAC	Male	All	+0.463	<.001	6	view →
LSCC	Female	All	+0.227	<.001	6	view →
LUAD	Male	All	+0.088	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

AKT2–HNSC

Open the HNSC breakdown →